Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter International Inc.

www.baxter.com

Latest From Baxter International Inc.

Appointments: Gyroscope, Urovant, Horizon, Modus, Allied Minds And Adherium

This week's roundup includes CEO appointments by Gyroscope Therapeutics, Urovant Sciences and Nevoii Pharmaceuticals, in addition to various other high-level appointments by companies including, Horizon Pharma, Veloxis Pharmaceuticals, Modus Therapeutics and Adherium.

Appointments BioPharmaceutical

Pacts In Medtech, July/August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in July and August 2017.

Deals Pacts in Medtech

Holding Out For Home Hemodialysis: Still-Modest Market Promises Bigger Growth

End-stage renal disease (ESRD) affects 600,000 Americans, striking over 120,000 people a year, and most of these patients require renal replacement therapy, such as hemodialysis. For most, that means a several-hour treatment, three times a week, at a dedicated outpatient center run by a service company like DaVita, Inc., or Fresenius Medical Care. But getting dialyzed at home is another option. Just under 2% of patients do home hemodialysis (HHD) today, but a growing number of companies are betting that this number could increase substantially.

Immunology Commercial

Quality Replay: Device History Record ‘Oversights’ A Clear Path To Quality Troubles, FDA Says

From our digital archives: Manufacturers are overlooking various key elements that should be included in device history records, including up-to-date labels, dates of product manufacture and missing signatures on documents, US FDA says. Because DHRs touch virtually every part of a firm’s quality system, a flawed DHR can prompt agency investigators to dig deeper during inspections. Experts from device firms Baxter and Thoratec weigh in.

Quality Control Compliance
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register